Breast
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Sacituzumab Govitecan in Previously Treated mTNBC
FEATURING
Adam Brufsky
- 14 views
- November 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-Year Outcomes From the NATALEE Trial
FEATURING
Peter Fasching
- 70 views
- November 19, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine in Early TNBC With Non-pCR
FEATURING
Sung-Bae Kim
- 69 views
- November 15, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TroFuse-010 Trial - Sacituzumab Tirumotecan ± Pembro vs. Chemo in HR+/HER2- Advanced BC
FEATURING
Sara Tolaney
- 262 views
- November 4, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Long-Term Outcomes and Treatment Strategies by ER Expression in Breast Cancer
FEATURING
Kazuki Nozawa
- 113 views
- October 29, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Outcomes in HR+/HER2- eBC by Prior Systemic Therapy - Insights From the NATALEE Trial Subgroup Analysis
FEATURING
Nicholas McAndrew
- 219 views
- October 25, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE
FEATURING
Sara Tolaney,
Hope Rugo
- 586 views
- October 4, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Breast12, CAPItello-290, and ICARUS-BREAST01
FEATURING
Sara Tolaney,
Hope Rugo
- 556 views
- October 4, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
FEATURING
Virginia Kaklamani
- 539 views
- September 23, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01
FEATURING
Paolo Tarantino
- 840 views
- September 24, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - AURORA Program, DAISY Trial, DESTINY-Breast06 Study, and Targeted Therapy Sequencing
FEATURING
Christos Sotiriou
- 543 views
- October 1, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond
FEATURING
Lisa Carey
- 371 views
- October 8, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in mBC
FEATURING
Giampaolo Bianchini
- 533 views
- October 1, 2024
- 8
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer
FEATURING
Jens Huober
- 352 views
- October 17, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimizing Precision Therapy in HR+/HER2- Advanced Breast Cancer Post-Endocrine + CDK4/6i
FEATURING
Philippe Aftimos
- 194 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC
FEATURING
Michail Ignatiadis
- 151 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Evaluation of Ivonescimab + CT and PM8002/BNT327 + Nab-Paclitaxel for 1L TNBC: Results From Two Studies
FEATURING
Carmen Criscitiello
- 166 views
- October 1, 2024
ecancer
ESMO 2024 Insights: Neo-CheckRay Trial - Durvalumab & Oleclumab Boost for SBRT + Chemo in ER+/HER2- eBC
FEATURING
Alex De Caluwe
- 16 views
- October 11, 2024
ecancer
ESMO 2024 Insights: WSG-TP-II Trial - ET + Trastuzumab & Pertuzumab vs. De-Escalated Chemo + Trastuzumab & Pertuzumab in HR+/HER2+ eBC
FEATURING
Oleg Gluz
- 43 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- and Node+ HR+/HER2- eBC From US Electronic Health Records
FEATURING
Komal Jhaveri
- 231 views
- October 17, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Ovarian Function Suppression in HR+ HER2+ Breast Cancer - Exploratory Analysis From HERA Trial
FEATURING
Sung Gwe Ahn
- 44 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: T-DXd in HER2+ mBC With or Without Brain Metastases - DESTINYBreast-12 Primary Results
FEATURING
Nancy Lin
- 214 views
- October 8, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Breast04 - Exploratory Biomarker Analysis of T-DXd vs. Physician’s Choice in HR+/HER2- mBC
FEATURING
Naoto Ueno
- 262 views
- October 9, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: A Registry-Based Study of pCR & Survival After Neoadjuvant Chemo in Stage I TNBC
FEATURING
Manon De Graaf
- 47 views
- October 1, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TRIPLE-B Study - 1L Carboplatin-Cyclophosphamide vs. Paclitaxel +/- Atezolizumab for mTNBC
FEATURING
Rosie Voorthuis
- 56 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Quantitative High Sensitivity HER2 Testing With Trastuzumab Deruxtecan in mBC
FEATURING
Paolo Tarantino
- 259 views
- October 1, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarchE Eligible Populations - A US Electronic Health Records Analysis
FEATURING
Paolo Tarantino
- 221 views
- September 27, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC
FEATURING
Giuseppe Viale
- 363 views
- September 23, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CAPItello-290 Trial - Capivasertib + Paclitaxel as 1L Treatment for mTNBC
FEATURING
Heather McArthur
- 140 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo + CT in High-Risk Early TNBC - OS Results From KEYNOTE-522
FEATURING
Heather McArthur
- 157 views
- September 24, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Prognostic Role of TILs on OS and Treatment De-Escalation in HER2+ Early BC in the ShortHER Trial
FEATURING
Maria Vittoria Dieci
- 108 views
- September 19, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DETECT V trial - Omission of Chemo and Addition of the CDK4/6i Ribociclib in HER2+ and HR+ mBC
FEATURING
Wolfgang Janni
- 31 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PROMENADE Trial - Pembro for Early ER-Low/HER2- BC - Real World French Cohort
FEATURING
Francois Cherifi
- 89 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Hypo vs. Normofractionated RT in eBC - 5-Year Results of HypoG-01
FEATURING
Sofia Rivera
- 165 views
- September 20, 2024
- 1